Nicotine Patch Safety Study
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-08-01
- Last Posted Date
- 2012-12-11
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 160
- Registration Number
- NCT01655082
Effect of F2695 on Functional Recovery After Ischemic Stroke
- First Posted Date
- 2012-07-12
- Last Posted Date
- 2015-04-01
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 532
- Registration Number
- NCT01639014
- Locations
- 🇧🇪
Clinique Saint-Joseph, Liege, Belgium
🇧🇪Regional Ziekenhuis Sint-Trudo, Sint-Truiden, Belgium
🇨🇿Litomyšlská Nemocnice, a.s., Litomyšl, Czech Republic
Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2014-01-15
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 206
- Registration Number
- NCT01604811
JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2015-12-08
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 69
- Registration Number
- NCT01599013
- Locations
- 🇫🇷
Pierre Fabre Research Institute, Boulogne, France
Effect of V0251 in Acute Vertigo
- First Posted Date
- 2012-04-24
- Last Posted Date
- 2014-10-30
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 132
- Registration Number
- NCT01583738
- Locations
- 🇭🇺
Pécsi Tudományegyetem Általános Orvostudományi Kar, Pecs, Hungary
🇪🇸Hospital Universitario La Fe, Valencia, Spain
🇭🇺Petz Aladár Megyei Oktató Kórház, Gyor, Hungary
Pilot Pharmacokinetic Study of New Nicotine Lozenge Formulations
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-04-10
- Last Posted Date
- 2012-07-10
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 13
- Registration Number
- NCT01574898
- Locations
- 🇫🇷
Eurofins Optimed, Gieres, France
Acute Sore Throat Pain Study
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2012-11-12
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 186
- Registration Number
- NCT01535079
- Locations
- 🇫🇷
Eurofins Optimed, Gières, France
🇫🇷Eurofins Optimed Lyon, Pierre Bénite, France
Efficacy and Safety Study in Patients Suffering From Knee Osteoarthritis
Not Applicable
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- Pierre Fabre Medicament
- Registration Number
- NCT01469507
Efficacy Emollient on Xerosis in Children With Atopic Dermatitis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 251
- Registration Number
- NCT01467362
- Locations
- 🇱🇹
Lithuania, Vilnius, Lithuania
🇵🇱Poland, Żyrardów, Poland
🇪🇪Estonia, Tartu, Estonia
Efficacy on Volume Reduction and Tolerance of Progressiv' Medical Compressive Therapy (MCT) V0322 BC in Patients With Chronic Venous Oedema
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2016-11-10
- Lead Sponsor
- Pierre Fabre Medicament
- Target Recruit Count
- 92
- Registration Number
- NCT01402921
- Locations
- 🇫🇷
Centre Hospitalo-Universitaire Grenoble, Grenoble, Isère, France
© Copyright 2024. All Rights Reserved by MedPath